



***In-vivo* detection of deep retinal neuronal layer changes following acute optic neuritis**

Omar Al-Louzi, MD; Pavan Bhargava, MD; Scott Newsome, DO; Peter Calabresi, MD; Shiv Saidha, MD

**Department of Neuroimmunology and Neuroinfectious disorders
Johns Hopkins University**

May 31, 2014

Disclosures


- Dr. Al-Louzi reports no disclosures.
- Dr. Bhargava reports no disclosures.
- Dr. Newsome has received consultation fees from Biogen-Idec and Genzyme as well as research support from Biogen-Idec and Novartis.
- Dr. Calabresi has received compensation for consulting and serving on scientific advisory boards from: Vaccinex, Vertex, Prothena, and Abbvie; and has received research funding for imaging research from NIH R01NS082347, NMSS, Race to Erase MS, and Novartis; and for unrelated research projects from Biogen-IDEc and MedImmune.
- Dr. Saidha receives funding support from the Race to Erase MS, and has received consulting fees from Medical Logix for the development of CME programs in neurology, consulting fees from Axon Advisors LLC, Educational Grant Support from Novartis & Teva Neurosciences, and speaking honoraria from the National Association of Managed Care Physicians.

Multiple sclerosis (MS)



- MS is an immune-mediated demyelinating disorder of the Central Nervous System (CNS) with both inflammatory and degenerative components.
- MS commonly involves the optic nerves; acute optic neuritis (AON) is the presenting feature in ~20% of patients, while 50% experience it at some point during the course of their disease¹.
- Autopsy studies demonstrate that optic nerve pathology is present in the majority of MS patients even in the absence of overt clinical involvement².

1. Balcer, L. J. Optic Neuritis. *N Engl J Med* 354, 1273–1280 (2006)
 2. Toussaint, D., P rier, O., Verstappen, A. & Bervoets, J. *Clin. Neuroophthalmol.* 3, 211–20 (1983).

Retinal histology




Microscopic cross-sectional view through the optic nerve including the retinal layers
<http://hubel.med.harvard.edu>




Optical coherence tomography (OCT)



- OCT is a technique that employs low coherence interferometry of near-infrared light.
- It is used to generate *in-vivo* high-resolution (< 5 μm), cross-sectional images of the retina.
- Because of the depth-resolving capacity of OCT, it enables visualization of retinal tissue structures similar to tissue sections under a microscope.



Evidence that retinal neuronal loss occurs in MS



Ganglion cell dropout (79% of MS patient eyeballs)
Inner nuclear layer neuron dropout (40% of MS patient eyeballs)
Green et al. Brain 2010; 133: 1591-601

- Retrograde neurodegeneration is thought to culminate in drop out of retinal ganglion cells.
- Our group has previously shown using macular segmentation that thinning of the composite ganglion cell + inner plexiform (GCIP) layers occurs following AON¹.
- However, comprehensive longitudinal *in-vivo* assessment of deep retinal neuronal layers following ON remains largely unexplored.

1. Syc, S. B. et al. Brain 135, 521-33 (2012).

Objectives

- To determine whether objective changes in INL and ONL thicknesses occur following AON.
- To explore whether these changes may be temporally related to thickness changes of the composite ganglion cell + inner plexiform layer thickness (GCIP).

Methods - Participants

- 34 patients diagnosed with acute unilateral demyelinating ON.
- Baseline evaluation was performed with a mean delay of 14 days from onset (SD 8.8, range: 1-33 days).
- A comparison cohort of 34 MS patients, who did not develop AON, were matched 1:1 based on age, sex, and duration of OCT follow-up.

Demographic and clinical characteristics


| | Patients presenting with AON at baseline | Patients with MS who did not develop AON at baseline or during follow-up | P-value |
|---|--|--|-------------------|
| Age, y, mean (SD) | 36.4 (9.4) | 35.9 (9.1) | 0.83 ^a |
| Female, n (%) | 30 (88) | 30 (88) | 1.00 ^b |
| Diagnosis, n (%) | | | |
| CIS | 7 (20.6) | 0 (0.0) | 0.01 ^b |
| RRMS | 26 (76.5) | 33 (97.1) | |
| SPMS | 1 (2.9) | 1 (2.9) | |
| Eyes with a previous history of AON, n (%) | 12 (17.6) | 19 (27.9) | 0.15 ^d |
| Follow-up duration, months, median (IQR; range) | 22.5 (12.6-34.2) | 22.9 (14.2-36.4) | 0.65 ^c |

Abbreviations: AON = Acute optic neuritis; MS = multiple sclerosis; CIS = clinically isolated syndrome; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; IQR = inter-quartile range.

^a Two-sample Student's *t*-test. ^b Fisher's exact test. ^c Mann-Whitney U test. ^d Chi-squared test.

Retinal imaging

- Patients underwent Cirrus-HD OCT imaging, with automated intra-retinal layer segmentation, at each study visit.
- Two macular segmentation methods were used to obtain measures of retinal layer thickness:
 1. Manufacturer's algorithm
 2. Graph-based, open-access method



Statistical analysis

- Time was taken as a continuous variable starting at the onset of AON symptoms.
- Comparisons between clinically affected and fellow eyes, at set time intervals, were done using mixed-effects linear regression accounting for within-subject inter-eye correlation.
- Multilevel linear spline models were used to analyze the course of OCT measure changes over time.
- Breakpoints (allowing for changes in slope to occur) were positioned, according to the best fit to the data.

Abbreviations: GCIP = ganglion cell+innerplexiform layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer; PRL = photoreceptor layer





Table 2: Estimated rates of change in average retinal layer thicknesses in clinically-affected eyes after ON


| OCT measure | | Baseline to 3 months | | 3 to 6 months | | 6 to 12 months | |
|-------------|--------------|---------------------------|---------|---------------------------|---------|---------------------------|---------|
| | | Rate of change (µm/month) | p-value | Rate of change (µm/month) | p-value | Rate of change (µm/month) | p-value |
| RNFL | | -9.85 | <0.001 | -0.91 | 0.713 | -0.36 | 0.695 |
| GCL+IPL | Manufacturer | -3.68 | <0.001 | 0.17 | 0.668 | -0.16 | 0.281 |
| | Graph-based | -2.70 | <0.001 | 0.11 | 0.731 | -0.14 | 0.220 |



Abbreviations: ON = optic neuritis; GCIP = ganglion cell layer + inner plexiform layer; RNFL = retinal nerve fiber layer.



Table 3: Estimated rates of change in average retinal layer thicknesses in clinically-affected eyes after ON

| OCT measure | Segmentation method | Baseline to 3 months | | 3 to 6 months | | 6 to 12 months | |
|-------------|---------------------|---------------------------|---------|---------------------------|---------|---------------------------|---------|
| | | Rate of change (µm/month) | p-value | Rate of change (µm/month) | p-value | Rate of change (µm/month) | p-value |
| INL+OPL | Manufacturer | 0.71 | <0.001 | -0.31 | 0.103 | 0.01 | 0.897 |
| | Graph-based | 0.11 | 0.417 | -0.26 | 0.061 | -0.04 | 0.506 |
| ONL+PRL | Manufacturer | 2.18 | <0.001 | -1.34 | <0.001 | -0.17 | 0.095 |
| | Graph-based | 1.37 | <0.001 | -0.65 | 0.001 | -0.15 | 0.038 |




Abbreviations: ON = acute optic neuritis; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer; PRL = photoreceptor segments layer.

Relationship between GCIP loss and ONL thickening at the 4±1 month visit



Take home messages

- Ganglion cell layer thinning following AON appears to be most rapid in the early months.
- OCT segmentation demonstrates a transient increase in ONL thickness that appears to be proportional to the degree of GCIP loss in affected eyes.
- This raises the possibility of biological trans-synaptic changes occurring in the deep retinal neuronal layers and may help us understand the cellular response to injury in MS.



Acknowledgements

Johns Hopkins Neurology

- Peter A. Calabresi
- Shiv Saidha
- Pavan Bhargava
- Scott Newsome

Johns Hopkins Electrical and Computer Engineering

- Jerry Prince
- Andrew Lang
- Aaron Carass

Johns Hopkins Biostatistics department:

- Ciprian Crainiceanu

Funding:

- NIH grant: 5R01NS082347-02
- Race to Erase MS